
3,0000
2,5000
2,0000
1,5000
1,0000
0,5000
0,0000
Optical density
0%
2%
4%
6%
8%
10%
12%
14%
16%
18%
PEG concentration, %
Acet, pH 5.0
His, pH 6.0
PB, pH 6.0
Cit, pH 5.0

Fig. 1.


0,08
0,07
0,06
0,05
0,04
0,03
0,02
0,01
0
Optical density
0%
2%
4%
6%
8%
10%
12%
14%
16%
18%
PEG concentration, %
4.5 mM His, pH 6.0
10 mM His, pH 6.0
20 mM His, pH 6.0
10 mM His, pH 5.5
10 mM His, pH 6.5

Fig. 2.


0,12
0,1
0,08
0,06
0,04
0,02
0
Optical density
0%
2%
4%
6%
8%
10%
12%
14%
16%
18%
PEG concentration, %
His + TRE
His + SUC
His + MAN
His + SORB

Fig. 3.


0,09
0,08
0,07
0,06
0,05
0,04
0,03
0,02
0,01
0,00
Optical density
0%
2%
4%
6%
8%
10%
12%
14%
16%
18%
PEG concentration, %
His+ MAN
His+ MAN + 0.1 PS80
His+ MAN + 0.2 PS80
His+ MAN + 0.5 PS80
His+ MAN + 1.0 PS80
His+ MAN + 0.1 Poloxamer
His+ MAN + 1.0 Poloxamer

Fig. 4


Percentage of PASI75 (%)
100
90
80
70
60
50
40
30
20
10
0
80 %
83.33 %
92.86 %
23.08 %
BCD-085 40 mg
BCD-085 80 mg
BCD-085 120 mg
Placebo

Fig. 5


Percentage of PASI75 (%)
100
80
60
40
20
0
0
4
8
12
Weeks
BCD-085 40 mg
BCD-085 80 mg
BCD-085 120 mg
Placebo

Fig. 6


PASI Improvement (%)
100
80
60
40
20
0
0
4
8
12
Weeks
BCD-085 40 mg
BCD-085 80 mg
BCD-085 120 mg
Placebo

Fig. 7


NAPSI percent Improvement (%)
60
40
20
0
BCD-085, 40 mg
BCD-085, 80 mg
BCD-085, 120 mg
Placebo

Fig. 8


Dose: 40
Dose: 80
Dose: 120
concentration (ng/ml)
28000
26000
24000
22000
20000
18000
16000
14000
12000
10000
8000
6000
4000
2000
0
-2000
0,0
0,5
1,5
4,0
8,0
24,0
48,0
72,0
144,0
168,0
Time (h)

Fig. 9


Dose: 40
Dose: 80
Dose: 120
60000
50000
40000
30000
20000
10000
0
-10000
Concentrations (ng/ml)
0,0
0,5
1,5
4,0
8,0
24,0
48,0
72,0
144,0
168,0
336,0
672,0
1008,0
1344,0
1680,0
2016,0
2352,0
Time(h)

Fig. 10


Group 2 (patients with PASI100)
BCD-085 80 mg q4w
Group 4 (patients with PASI<100)
BCD-085 80 mg q2w
Group 1 (patients with PASI100)
BCD-085 120 mg q4w
Group 3 (patients with PASI<100)
BCD-085 120 mg q2w
PASI100
Group 1 (patients with PASI≥50)
BCD-085 80 mg q2w
Group 2 (patients with PASI<50)
BCD-085 120 mg q2w
PASI50
0
14
26
52
56
BCD-085-2
Open label extension study
Follow up

Fig. 11


Patients achieving PASI75 (%)
100
90
80
70
60
50
40
30
20
10
0
100 %
97.44 %
95.24 %
100 %
Week 38
BCD-085 120 mg (Q2W / Q4W)
BCD-085 80 mg (Q2W / Q4W)
BCD-085 120 mg (Q2W)
BCD-085 80 mg (Q2W)

Fig. 12


Patients achieving PASI90 (%)
100
90
80
70
60
50
40
30
20
10
0
100 %
97.44 %
80.95 %
91.89 %
Week 38
BCD-085 120 mg (Q2W / Q4W)
BCD-085 80 mg (Q2W / Q4W)
BCD-085 120 mg (Q2W)
BCD-085 80 mg (Q2W)

Fig. 13


Patients achieving PASI100 (%)
100
90
80
70
60
50
40
30
20
10
0
100 %
82.05 %
33.33 %
43.24 %
Week 38
BCD-085 120 mg (Q2W / Q4W)
BCD-085 80 mg (Q2W / Q4W)
BCD-085 120 mg (Q2W)
BCD-085 80 mg (Q2W)

Fig. 14


Patients achieving sPGA score 0-1 (%)
100
90
80
70
60
50
40
30
20
10
0
100 %
97.44 %
95.24 %
91.89 %
Week 38
BCD-085 120 mg (Q2W / Q4W)
BCD-085 80 mg (Q2W / Q4W)
BCD-085 120 mg (Q2W)
BCD-085 80 mg (Q2W)

Fig. 15


Patients achieving sPGA score 0 (%)
100
90
80
70
60
50
40
30
20
10
0
100 %
79.49 %
33.33 %
45.95 %
Week 38
BCD-085 120 mg (Q2W / Q4W)
BCD-085 80 mg (Q2W / Q4W)
BCD-085 120 mg (Q2W)
BCD-085 80 mg (Q2W)

Fig. 16


Group 1 (n = 85):
BCD-085 120 mg s/c once at weeks 0, 1, 2, 4, 6, 8, 10 then every 4 weeks
Group 2[a] (n = 85):
BCD-085 120 mg s/c once at weeks 0, 1, 2, 6, 10 then every 4 weeks
Group 3 : BCD-085 120 mg s/c at weeks 12, 13, 14 then every 4 weeks
Group 3 (n = 43):
Placebo s/c
at weeks 0, 1, 2, 4, 6, 8, 10
Follow-up
4 weeks
Follow-up
4 weeks
Follow-up
Screening
28 days
12 недель
-4
0
8
12
54
154
158
166
170
Blinded therapy
Unblinded therapy
The main period
OLE
hypotheses testing
a. Patients from Group 2 will be given two SC injections of placebo (1.0 mL each) on Day 1 of Weeks 4 and 8

Fig. 17


Percentage of patients (%)
100
75
50
25
0
77.65 %
83.33 %
0 %
55.29 %
55.95 %
0 %
29.41 %
33.33 %
0 %
81.18 %
79.76 %
2.27 %
PASI 75
PASI 90
PASI 100
sPGA
BCD-085 Q2W
BCD-085 Q4W
Placebo

Fig. 18


IMPROVEMENT
PASI percent improvement (%)
100
90
80
70
60
50
40
30
20
10
0
0
8
12
Week
BCD-085 Q2W
BCD-085 Q4W
Placebo

Fig.19


IMPROVEMENT
Change in itch severity (VAS, mm)
0
-10
-20
-30
0
1
12
Week
BCD-085 Q2W
BCD-085 Q4W
Placebo

Fig.20


IMPROVEMENT
DLQI total score (change from baseline)
0.0
-2.5
-5.0
-7.5
-10.0
0
8
12
Week
BCD-085 Q2W
BCD-085 Q4W
Placebo

Fig.21


NAPSI score change (score)
0
-3
-6
-9
-11
-7
0
Week 12
BCD-085 Q2W
BCD-085 Q4W
Placebo

Fig. 22


Percentage of patients (%)
100
75
50
25
0
ACR 20
ACR 50
ACR 70
83.33 %
85.71 %
0 %
50 %
28.57 %
0 %
16.67 %
14.29 %
0 %
BCD-085 Q2W
BCD-085 Q4W
Placebo

Fig. 23


BCD-085, 40 mg
BCD-085, 80 mg
BCD-085, 120 mg
Placebo
Percentage of ASAS20 (%)
0
10
20
30
40
50
60
70
80
90
100
Week 4
Week 8
Week 12
Week 16
72.73 %
77.27 %
81.82 %
33.33 %
63.64 %
72.73 %
77.27 %
33.33 %
72.73 %
86.36 %
42.86 %
72.73 %
81.82 %
90.91 %
42.86 %

Fig. 24


A
Percentage of ASAS20 (%)
Weeks
NTK 40mg
NTK 80 mg
NTK 120 mg
placebo
B
Percentage of ASAS40 (%)
C
Percentage of ASAS 5/6 (%)
D
Spinal pain, score

Fig. 25


Anti-IL-17 concentration, ng/mL
26000
24000
22000
20000
18000
16000
14000
12000
10000
8000
6000
4000
2000
0
-2000
0.0
0.5
1.5
4.0
8.0
24.0
48.0
72.0
144.0
168.0
Time (h)
BCD-085 (40 mg)
BCD-085 (80 mg)
BCD-085 (120 mg)

Fig. 26


60000
50000
40000
30000
20000
10000
0
-10000
Anti-IL-17 concentration, ng/mL
0.0
0.5
1.5
4.0
8.0
24.0
48.0
72.0
144.0
168.0
336.0
672.0
1008.0
1344.0
1680.0
2016.0
2352.0
2688.0
Time (h)
BCD-085 (40 mg)
BCD-085 (80 mg)
BCD-085 (120 mg)

Fig. 27


0
16
28
40
52
56
BCD-085-3
Open label extension study
Follow up
ASAS20
Group 1 (patients who reached ASAS20)
BCD-085 80 mg q2w
Group 2 (patients who didn't reach ASAS20)
BCD-085 120 mg q2w
ASAS20
ASAS20
ASAS20

Fig. 28


ASAS20/40 at Wk 16
Percentage of patients (%)
70
60
50
40
30
20
10
0
60.53 %
2.63 %
40.35 %
2.63 %
ASAS20
ASAS40
NTK (114 pts)
Placebo (114 pts)

Fig. 29


Secondary endpoints (mean change from baseline at Wk 16)
Score
3
2
1
0
-1
-2
-3
-4
0.095
0.2
0.2
0.9
0
-1.53
-2.8
-0.4
-0.9
-1
ASDAS-CRP
BASDAI
BASMI
BASFI
MASES
NTK
Placebo

Fig. 30


Mean change from baseline in MRI scores at Wk 16
Score
0
-2
-4
-6
-8
-10
-2.161
-0.297
-3.804
-1.82
Berlin spine score
SPARCC score
NTK (n=114)
PBO (n=114)

Fig. 31


8
7
6
5
4
3
2
1
0
6.82
6.68
5.84
4.76*
5.57
4.43*
5.57
4.21*
5.66
3.77*
6.34
3.85*
7.06
3.71*
Screening
Wk 1
Wk 2
Wk 4
Wk 8
Wk12
Wk 16
NTK (n=114)
PBO (n=114)

Fig. 32


8
6
4
2
0
-2
-4
BASDAI
BASFI
SF36 PC
SF36 MC
0.2
-2.8
0.9
-0.9
6.3
-2.6
2.4
1.1
NTK (n=114)
PBO (n=114)

Fig. 33